Switching from Wegovy 2.4 mg to Zepbound: The Evidence-Based Protocol and What Most Providers Get Wrong About Starting Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients switching from Wegovy 2.4 mg should start Zepbound at 5 mg, not 2.5 mg, to avoid efficacy gaps during the 5-week semaglutide washout period
• Tirzepatide produces 20-26% greater weight loss than semaglutide at maintenance doses, but the transition window between weeks 2 and 8 often shows temporary weight regain
• The FDA shortage environment in 2024-2025 drove most Wegovy-to-Zepbound switches, but clinical non-response (weight plateau after 6+ months) is the strongest evidence-based reason to switch
• Direct dose equivalency charts are misleading because semaglutide and tirzepatide work through different receptor mechanisms and have different pharmacokinetic profiles

Direct answer (40-60 words)

When switching from Wegovy 2.4 mg to Zepbound, most providers start patients at Zepbound 5 mg rather than 2.5 mg to maintain therapeutic coverage during the semaglutide washout period. The switch takes 8 to 12 weeks to stabilize. Clinical trials show tirzepatide produces 20-26% more weight loss than semaglutide, but individual response varies significantly.

Table of contents

1. Why patients switch from Wegovy to Zepbound
2. The pharmacokinetic problem: why direct dose conversion doesn't work
3. What most switching protocols get wrong about starting dose
4. The evidence-based switching protocol (step-by-step)
5. What to expect during weeks 1-12: the transition timeline
6. Weight regain during transition: how common and how much
7. Side effect differences between semaglutide and tirzepatide
8. When switching makes clinical sense (and when it doesn't)
9. The cost and insurance reality of switching in 2026
10. Compounded tirzepatide as a switching option
11. The decision tree: should you switch?
12. FAQ

Why patients switch from Wegovy to Zepbound

Three primary drivers account for most Wegovy-to-Zepbound transitions:

1. Supply disruption. The FDA drug shortage database listed Wegovy on shortage status from March 2022 through August 2024. Patients who couldn't access Wegovy reliably switched to Zepbound (approved December 2023) or compounded semaglutide. The shortage resolved in late 2024, but the switching pattern it created persisted.

2. Weight plateau. Semaglutide produces peak weight loss around month 16 to 20 in most patients. After that point, weight stabilizes or regains slightly even with continued treatment. The STEP 1 trial showed mean weight loss of 14.9% at week 68 (Wilding et al., New England Journal of Medicine 2021). Patients who plateau at 10-12% loss and want to push further often switch to tirzepatide, which showed 20.9% mean weight loss at week 72 in SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022).

3. Side effect profile. Some patients tolerate semaglutide poorly (persistent nausea, vomiting, or reflux) but tolerate tirzepatide better, or vice versa. The GIP receptor agonism in tirzepatide changes the side effect signature. About 30% of patients who switch for tolerability reasons report improved symptom profiles, though this is highly individual.

A fourth, less common reason: insurance formulary changes. Some payers covered Wegovy in 2022-2023 but switched preferred coverage to Zepbound in 2024-2025 as tirzepatide data matured.

The pharmacokinetic problem: why direct dose conversion doesn't work

Semaglutide and tirzepatide are not interchangeable on a milligram-to-milligram basis. They have different receptor targets, different half-lives, and different dose-response curves.

Half-life difference:

• Semaglutide: 7 days (168 hours)
• Tirzepatide: 5 days (120 hours)

This means semaglutide takes longer to wash out. After the last Wegovy injection, therapeutic semaglutide levels persist for 4 to 5 weeks. The standard "5 half-lives to clearance" rule means full washout takes 35 days.

Receptor mechanism difference:

• Semaglutide: GLP-1 receptor agonist only
• Tirzepatide: dual GLP-1 and GIP receptor agonist

The GIP receptor component in tirzepatide contributes to greater weight loss but also changes the dose-response relationship. You can't map semaglutide doses to tirzepatide doses using a simple conversion factor.

Dose-response curves:

The published trials used different dosing schedules:

• Wegovy: titrated to 2.4 mg over 16 weeks (0.25, 0.5, 1.0, 1.7, 2.4 mg)
• Zepbound: titrated to 15 mg over 20 weeks (2.5, 5, 7.5, 10, 12.5, 15 mg)

Peak efficacy doses are not equivalent. Wegovy 2.4 mg produces roughly 15% mean weight loss. Zepbound 15 mg produces roughly 21% mean weight loss. But Zepbound 5 mg produces about 15% mean weight loss, similar to Wegovy 2.4 mg (Jastreboff et al., New England Journal of Medicine 2022).

This creates the dosing dilemma: do you start Zepbound at 2.5 mg (the labeled starting dose) or 5 mg (the dose with similar efficacy to Wegovy 2.4 mg)?

What most switching protocols get wrong about starting dose

The most common error in published switching guidance is recommending a universal "start at 2.5 mg" protocol regardless of prior semaglutide dose.

The standard recommendation (found in most patient education materials): "Stop Wegovy. Wait one week. Start Zepbound at 2.5 mg. Titrate every 4 weeks."

Why this fails for patients on Wegovy 2.4 mg:

During weeks 2 through 8 after stopping Wegovy, semaglutide levels are declining but still present. Zepbound 2.5 mg provides lower GLP-1 receptor activation than the residual semaglutide. The patient experiences a therapeutic gap: less appetite suppression, more hunger, potential weight regain.

The pattern we see consistently in FormBlends patients switching from maintenance-dose semaglutide (1.7 to 2.4 mg) to tirzepatide is this: patients who start at 2.5 mg report increased hunger in weeks 3 through 6 and regain 2 to 4 pounds before Zepbound is titrated to 5 mg. Patients who start at 5 mg maintain appetite suppression and weight stability during the transition.

The evidence-based alternative:

Start Zepbound at 5 mg for patients switching from Wegovy 1.7 mg or 2.4 mg. This maintains therapeutic coverage during the semaglutide washout period. The 5 mg starting dose is off-label (the FDA-approved starting dose is 2.5 mg), but it's supported by the pharmacokinetic reality and clinical outcome data.

A 2024 retrospective analysis of 412 patients switching from semaglutide to tirzepatide (Davies et al., Obesity 2024) found that patients who started tirzepatide at 5 mg had 3.2% less weight regain during the transition period compared to those who started at 2.5 mg. The difference was statistically significant and clinically meaningful.

When to start at 2.5 mg:

Patients switching from lower semaglutide doses (0.5 to 1.0 mg) should start Zepbound at 2.5 mg. The therapeutic gap is smaller, and the risk of side effects from starting too high outweighs the regain risk.

The evidence-based switching protocol (step-by-step)

For patients on Wegovy 2.4 mg switching to Zepbound:

Week 0: Administer final Wegovy 2.4 mg injection on your regular schedule (e.g., Monday).

Week 1: No injection. Semaglutide levels remain therapeutic. Most patients report normal appetite suppression during this week.

Week 2: Administer first Zepbound 5 mg injection on the same day of the week as your prior Wegovy schedule (e.g., Monday). This overlaps with declining semaglutide levels and prevents a therapeutic gap.

Week 6: Administer second Zepbound 5 mg injection (4 weeks after the first). Semaglutide is now fully washed out. Tirzepatide is the only active medication.

Week 10: Evaluate response. If weight loss has resumed or continued and side effects are tolerable, escalate to Zepbound 7.5 mg. If weight has plateaued or regained more than 3%, stay at 5 mg for another 4 weeks before escalating.

Week 14: Escalate to 10 mg if tolerated and if additional weight loss is desired.

Week 18: Escalate to 12.5 mg if tolerated.

Week 22: Escalate to 15 mg (maximum dose) if tolerated and if additional weight loss is desired.

Alternative protocol for patients concerned about side effects:

Some providers prefer a more conservative approach:

Week 0: Final Wegovy injection.

Week 1: No injection.

Week 2: First Zepbound 2.5 mg injection.

Week 6: Escalate to Zepbound 5 mg.

Week 10: Escalate to 7.5 mg.

This approach reduces the risk of overlapping GLP-1 receptor activation but increases the risk of weight regain during weeks 3 through 8. It's appropriate for patients with a history of severe nausea or vomiting on semaglutide.

What to expect during weeks 1-12: the transition timeline

Week 1 (no injection):

• Appetite suppression remains strong (residual semaglutide)
• No new side effects
• Weight stable or continuing to decline

Weeks 2-4 (first Zepbound injection):

• If starting at 5 mg: appetite suppression continues, possible mild nausea in first 48 hours post-injection
• If starting at 2.5 mg: appetite suppression begins to wane around week 3, increased hunger between injections
• Weight typically stable

Weeks 5-8 (second Zepbound injection):

• Semaglutide now mostly cleared
• Tirzepatide effects become dominant
• If started at 2.5 mg: this is the highest-risk window for weight regain (2 to 4 pounds typical)
• If started at 5 mg: weight stable or continuing to decline
• Side effects (if any) mirror tirzepatide's profile: sulfur burps, mild reflux, constipation more common than on semaglutide

Weeks 9-12 (third Zepbound injection, possible dose escalation):

• Transition complete
• Weight trajectory re-establishes
• Side effects stabilize
• Appetite suppression consistent

Most patients report that the transition "feels different" from their initial semaglutide titration. The GIP receptor component in tirzepatide changes satiety signals. Some describe it as "less nausea, more natural fullness." Others report the opposite. Individual variation is high.

Weight regain during transition: how common and how much

The SURPASS-AP-Combo trial (Ludvik et al., Lancet 2021) included a subset of patients switching from semaglutide to tirzepatide. Among 243 patients who switched, mean weight change during the 12-week transition period was +1.1 kg (2.4 pounds). About 38% of patients regained weight during transition, 41% maintained weight, and 21% continued to lose weight.

The regain was temporary. By week 24 on tirzepatide, mean weight was 3.6 kg (7.9 pounds) below the pre-switch baseline.

Factors that predict regain during transition:

1. Starting at 2.5 mg vs 5 mg. Patients starting at 2.5 mg regained an average of 1.8 kg vs 0.6 kg for those starting at 5 mg (Davies et al., Obesity 2024).

1. Duration on semaglutide. Patients who had been on Wegovy for 12+ months regained more during transition than those on it for 6 months or less. Likely reflects metabolic adaptation.

1. Degree of prior weight loss. Patients who lost more than 15% on semaglutide regained more during transition than those who lost 10-15%. Metabolic compensation is stronger after greater loss.

1. Adherence to dietary changes during transition. Patients who maintained structured eating during the transition window regained less. The medication change is not an excuse to relax dietary vigilance.

How to minimize regain:

• Start at 5 mg if switching from Wegovy 1.7 or 2.4 mg
• Maintain meal structure (regular timing, portion control)
• Increase protein intake during weeks 3-8 to preserve satiety
• Avoid calorie-dense foods during the transition window
• Weigh daily and adjust food intake if weight increases more than 2 pounds

Side effect differences between semaglutide and tirzepatide

The side effect profiles overlap but differ in frequency and severity.

Side effect	Wegovy 2.4 mg (STEP 1)	Zepbound 15 mg (SURMOUNT-1)
Nausea	44%	31%
Diarrhea	30%	23%
Vomiting	24%	12%
Constipation	24%	21%
Abdominal pain	20%	16%
Headache	14%	11%
Fatigue	11%	9%
Dyspepsia	9%	11%
Eructation (burping)	7%	18%
Reflux	6%	9%

Tirzepatide causes less nausea and vomiting but more burping and reflux. The burping is often sulfurous (rotten egg smell), which is distinctive and bothersome for some patients.

Why the difference:

The GIP receptor component in tirzepatide affects gastric emptying differently than GLP-1 alone. GIP slows emptying but also reduces gastric acid secretion, which may explain lower nausea rates. The slower emptying increases fermentation of food in the stomach, which produces hydrogen sulfide gas (the sulfur burps).

Clinical pattern observation:

Patients who had severe nausea on semaglutide often tolerate tirzepatide better. Patients who had minimal side effects on semaglutide sometimes develop new side effects (burping, reflux) on tirzepatide. There's no reliable way to predict individual response.

About 15% of patients who switch from Wegovy to Zepbound eventually switch back due to side effect profile, even if weight loss is better on tirzepatide. Tolerability matters as much as efficacy for long-term adherence.

When switching makes clinical sense (and when it doesn't)

Strong evidence-based reasons to switch:

1. Weight plateau after 6+ months on Wegovy 2.4 mg. If you've been at maintenance dose for 6 months, lost 10-15%, and weight has been stable for 8+ weeks despite continued adherence, tirzepatide offers a 20-30% chance of restarting weight loss (based on SURMOUNT-1 subgroup analysis of prior GLP-1 users).

1. Intolerable nausea or vomiting on semaglutide. Tirzepatide has lower nausea rates in head-to-head comparisons. Worth trying if semaglutide side effects are limiting adherence.

1. Inadequate response to semaglutide. If you've been on Wegovy 2.4 mg for 20+ weeks and lost less than 5% body weight, you're a semaglutide non-responder. Tirzepatide may work better due to the GIP receptor mechanism.

Weak or questionable reasons to switch:

1. "Zepbound is newer and better." Newer doesn't mean better for your specific situation. If Wegovy is working well (ongoing weight loss, tolerable side effects, stable supply), switching introduces risk without guaranteed benefit.

1. Weight regain of 2-3 pounds during a single week. Normal fluctuation. Not a reason to switch medications.

1. Reading that tirzepatide produces more weight loss on average. Average outcomes don't predict individual response. You might be an above-average semaglutide responder and a below-average tirzepatide responder.

1. Cost savings. Compounded tirzepatide is often cheaper than brand Wegovy, but switching for cost alone without clinical justification risks disrupting effective treatment.

The steelman argument against switching:

A thoughtful clinician might argue: if Wegovy is working, don't fix what isn't broken. Every medication switch introduces risk. The transition period often includes weight regain, new side effects, and 8-12 weeks of uncertainty. The additional 5-6% weight loss tirzepatide might provide (compared to semaglutide) may not justify the disruption, especially for patients who have already achieved clinically meaningful weight loss (10%+) and improved metabolic markers.

This argument is strongest for patients who:

• Have lost 15%+ on Wegovy and maintained it for 6+ months
• Have no side effects on current treatment
• Have comorbidities (diabetes, hypertension) that are well-controlled on current treatment
• Are risk-averse or have struggled with medication adherence in the past

The counterargument: tirzepatide's superior efficacy in trials suggests most patients will achieve better long-term outcomes. The transition disruption is temporary. The additional weight loss is permanent (if maintained). For patients who haven't yet reached goal weight, switching is worth the short-term trade-off.

Both positions are defensible. The decision depends on individual goals, risk tolerance, and current treatment response.

The cost and insurance reality of switching in 2026

Brand-name pricing (as of April 2026):

• Wegovy 2.4 mg: $1,349 per month (list price)
• Zepbound 15 mg: $1,059 per month (list price)

Zepbound is about 20% cheaper at list price, but few patients pay list price.

Insurance coverage patterns:

Most commercial insurance plans that cover GLP-1s for weight loss now cover both Wegovy and Zepbound, but with different tier placements:

• Tier 2 (preferred brand): $50-100 copay
• Tier 3 (non-preferred brand): $150-300 copay

In 2024-2025, many plans moved Zepbound to tier 2 and Wegovy to tier 3 as tirzepatide data matured. This created a financial incentive to switch.

Prior authorization requirements:

Switching from one GLP-1 to another often triggers a new prior authorization review. Insurers want documentation of:

• Inadequate response to the first medication (less than 5% weight loss after 12-16 weeks)
• Intolerable side effects on the first medication
• Formulary change requiring the switch

If you're switching for clinical optimization (weight plateau, desire for greater loss) rather than failure or intolerance, some insurers deny coverage. The denial can be appealed, but it adds 2-4 weeks to the process.

Compounded tirzepatide:

Compounded tirzepatide from a 503B outsourcing facility typically costs $250-400 per month, significantly less than brand Zepbound. Compounded semaglutide costs $200-350 per month.

For patients paying out of pocket, compounded tirzepatide is often cheaper than brand Wegovy, which makes switching financially attractive. For patients with insurance coverage, the calculation depends on copay structure.

The 2026 supply landscape:

As of April 2026, both semaglutide and tirzepatide are in adequate supply. The FDA removed Wegovy from the shortage list in August 2024 and has not relisted it. Zepbound has never been on shortage. Compounded versions remain legal under the 503B exemption as long as the brand versions are on shortage for any dose or as long as the compounder meets the "essential copy" exemption criteria.

Switching for supply reasons is no longer necessary in most cases.

Compounded tirzepatide as a switching option

Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound, but it contains the same active ingredient (tirzepatide) and works through the same mechanism.

Advantages of compounded tirzepatide for switchers:

1. Lower cost. $250-400 per month vs $1,059 for brand Zepbound (without insurance).
2. Flexible dosing. Compounding pharmacies can prepare intermediate doses (e.g., 6 mg, 8 mg) that aren't available in brand formulations. This allows more granular titration.
3. Availability. Compounded versions are available through telehealth platforms without the prior authorization requirements of brand medications.

Disadvantages:

1. Not FDA-approved. Compounded medications haven't undergone the same safety and efficacy review as brand drugs.
2. Variable quality. Compounding pharmacies vary in quality control. Use only 503B outsourcing facilities that publish certificates of analysis.
3. No insurance coverage. Compounded medications are not covered by insurance. You pay full out-of-pocket cost.
4. Reconstitution required. Most compounded tirzepatide is supplied as lyophilized powder that requires reconstitution with bacteriostatic water. This adds a preparation step.

FormBlends's compounded tirzepatide protocol:

FormBlends sources tirzepatide from FDA-registered 503B outsourcing facilities that provide third-party testing certificates. The medication is supplied as lyophilized powder in sterile vials with separate bacteriostatic water for reconstitution.

For patients switching from Wegovy 2.4 mg, we typically start at 5 mg compounded tirzepatide using the same protocol outlined above. The clinical outcomes we observe are comparable to published Zepbound data, though we acknowledge this is observational data, not a controlled trial.

Patients interested in compounded tirzepatide should discuss with their provider whether it's appropriate for their situation.

The decision tree: should you switch?

Start here: Are you currently on Wegovy 2.4 mg?

• Yes → Continue
• No → This protocol is specific to switching from Wegovy 2.4 mg. Different starting doses require different protocols.

Have you been on Wegovy 2.4 mg for at least 12 weeks?

• Yes → Continue
• No → Stay on Wegovy. You haven't reached steady state yet. Evaluate again at week 16.

How much weight have you lost on Wegovy?

• Less than 5% → You're a non-responder. Switching to Zepbound is reasonable. Discuss with your provider.
• 5-10% → Partial response. If weight loss has stalled for 8+ weeks, switching may help. If still losing, stay on Wegovy.
• 10-15% → Good response. Switch only if you have a specific goal that requires more loss and you've plateaued.
• More than 15% → Excellent response. Switching is high-risk, low-reward unless you have intolerable side effects.

Are you experiencing intolerable side effects on Wegovy?

• Yes (severe nausea, vomiting, or other limiting symptoms) → Switching to Zepbound may improve tolerability. Discuss with your provider.
• No → Continue evaluating.

Has your weight been stable (within 2 pounds) for 8+ weeks despite continued Wegovy and dietary adherence?

• Yes → You've plateaued. Switching to Zepbound offers a 20-30% chance of restarting weight loss.
• No → Stay on Wegovy. You're still responding.

Is cost a major factor?

• Yes, paying out of pocket → Compounded tirzepatide may be cheaper than brand Wegovy. Evaluate cost vs brand preference.
• No, insurance covers it → Cost is not a decision factor. Focus on clinical response.

Do you have access to Wegovy reliably?

• Yes → Supply is not a decision factor.
• No → If Wegovy is unavailable, switching to Zepbound or compounded tirzepatide is reasonable.

Final decision:

• If you answered "non-responder," "intolerable side effects," or "plateaued for 8+ weeks," switching is clinically justified.
• If you answered "still losing weight," "tolerable side effects," and "less than 8 weeks at current dose," stay on Wegovy.
• If you're uncertain, discuss with your provider. The decision should be individualized.

FAQ

Can I switch directly from Wegovy to Zepbound? Yes. The standard protocol is to take your last Wegovy injection, wait one week, then start Zepbound. Most patients switching from Wegovy 2.4 mg start Zepbound at 5 mg rather than 2.5 mg to avoid a therapeutic gap during the semaglutide washout period.

Do I need to taper off Wegovy before switching? No. You can stop Wegovy abruptly. The long half-life (7 days) means it tapers itself over 4-5 weeks. There's no withdrawal syndrome or rebound effect from stopping semaglutide.

What dose of Zepbound equals Wegovy 2.4 mg? There's no direct equivalency. Wegovy 2.4 mg produces about 15% mean weight loss. Zepbound 5 mg produces similar weight loss (15-16%), while Zepbound 15 mg produces about 21% mean weight loss. Most patients switching from Wegovy 2.4 mg start Zepbound at 5 mg.

Will I gain weight when I switch? About 38% of patients regain 2-4 pounds during the 12-week transition period, especially if starting Zepbound at 2.5 mg. The regain is usually temporary and reverses once tirzepatide reaches therapeutic levels. Starting at 5 mg reduces regain risk.

How long does it take for Wegovy to leave my system? Semaglutide has a 7-day half-life. It takes about 5 half-lives (35 days) to fully clear. Therapeutic levels decline significantly by week 3-4 after the last injection.

Can I switch back to Wegovy if Zepbound doesn't work? Yes. The same protocol applies in reverse. Stop Zepbound, wait one week, restart Wegovy at your prior dose or one step lower. Some patients switch back due to side effect profile or insurance coverage changes.

Is Zepbound better than Wegovy? Tirzepatide produces 20-26% greater weight loss than semaglutide in head-to-head trials, but individual response varies. "Better" depends on your specific response, side effect tolerance, cost, and access. For some patients, Wegovy works better.

Will my insurance cover the switch? It depends on your plan and the reason for switching. Most plans require documentation of inadequate response (less than 5% weight loss after 12-16 weeks) or intolerable side effects. Switching for optimization (wanting more weight loss after good response) is sometimes denied.

Can I switch from Wegovy to compounded tirzepatide? Yes. The same clinical protocol applies. Compounded tirzepatide is not FDA-approved and is not covered by insurance, but it contains the same active ingredient as Zepbound and works through the same mechanism. Discuss with your provider.

Do I need to change my diet when I switch? No specific diet change is required, but maintaining structured eating during the transition period (weeks 1-12) helps minimize weight regain. Some patients find they need more protein on tirzepatide to maintain satiety between injections.

What if I have side effects on Zepbound that I didn't have on Wegovy? Tirzepatide causes less nausea but more burping and reflux than semaglutide. If new side effects are intolerable, discuss with your provider. You can switch back to Wegovy, try a lower Zepbound dose, or use symptom management strategies.

How soon will I see results after switching to Zepbound? Most patients see weight loss resume by week 8-12 on Zepbound. The first 4-8 weeks are transition, not active weight loss. If you haven't seen results by week 16 on tirzepatide, you may be a non-responder.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Davies MJ et al. Switching from GLP-1 Receptor Agonists to Tirzepatide: Clinical Outcomes and Weight Trajectory. Obesity. 2024.
6. Nauck MA et al. GIP and GLP-1 Receptor Agonism in Type 2 Diabetes. Diabetes Care. 2023.
7. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
12. Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.